UnitedHealthcare Sacral Nerve Stimulation Coverage

Coverage Criteria for Sacral Nerve Stimulation

Sacral nerve stimulation screening trial — urinary

Covered when ALL of the following are met:

Urinary screening trial criteria: Overactive bladder symptoms (urgency/frequency) or other lower urinary tract symptoms including urge incontinence, bladder capacity >= 100 mL, or nonobstructive urinary retention; symptoms are not secondary to neurologic disease (e.g., Parkinson's disease, stroke, spinal cord injury, multiple sclerosis); symptoms refractory to conservative care (e.g., bladder training, pelvic floor rehabilitation, pharmacologic therapy); no bladder outlet or mechanical obstruction (e.g., BPH, tumor/radiation-induced obstruction, urethral stricture); individual capable of operating sacral nerve stimulating devicebladder capacity >= 100 mL

Applies to individuals 2 years of age and older

Sacral nerve stimulation permanent implantation — urinary

Covered when ALL of the following are met:

Urinary permanent implantation criteria: Improvement in reported symptoms of 50% or greater in response to a screening trial of sacral nerve stimulation; and all criteria for sacral nerve stimulation screening trial have been met>=50% improvement

Replacement or revision considered when existing device is nonfunctional and cannot be repaired or is no longer under warranty

Sacral nerve stimulation screening trial — fecal

Covered when ALL of the following are met:

Fecal screening trial criteria: Symptoms refractory to conservative care (e.g., bowel training, bulking agents, pelvic floor rehabilitation, pharmacological therapy); individual capable of operating sacral nerve stimulating device; fecal incontinence is not secondary to constipation; fecal incontinence is not secondary to neurologic disease (e.g., Parkinson's disease, stroke, spinal cord injury, multiple sclerosis); absence of distorted anorectal anatomy (e.g., anorectal malformation, abscess/fistula, prior rectal surgery)

Sacral nerve stimulation permanent implantation — fecal

Covered when ALL of the following are met:

Fecal permanent implantation criteria: Improvement in reported symptoms of 50% or greater in response to a screening trial of sacral nerve stimulation; and all criteria for sacral nerve stimulation screening trial for fecal incontinence have been met>=50% improvement

Unproven / Not medically necessary

Unproven indications: Sacral nerve stimulation for treatment of Constipation and Chronic Pelvic Pain is considered unproven and not medically necessary due to insufficient evidence of safety and/or efficacy

Study-derived implant candidacy

Common study-based criteria for proceeding to permanent SNM implant included ALL of the following in many trials:

Test-phase response requirements: ≥50% improvement in target symptom (e.g., urinary urgency incontinence episodes, urinary frequency) or return to <8 voids/day for frequency indications≥50%

Used repeatedly as the success threshold in trials and as a criterion for permanent implant

Prior treatments: Failure of conservative management and often failure of at least one pharmacologic therapy (or prior botulinum toxin in some cohorts)

Many trials enrolled refractory patients and some analyses specifically assessed SNM after failed BTX

Indication-specific evidence summaries

Summary of evidence strength and outcomes by indication:

OAB/UUI: Randomized trials and meta-analyses demonstrate SNM reduces incontinence episodes and voiding frequency versus baseline and, in some trials, versus standard medical therapy; sustained improvements in quality of life reported with device-related adverse events including pain, infection, loss of effectiveness, and lead migration

Siegel and other RCTs and meta-analyses report durable benefit through multiple years

Neurogenic LUTD: Systematic reviews report pooled test-phase SNM success (~66.2%) and pooled permanent SNM success (~84.2%) with variable results by neurogenic condition; evidence limited by heterogeneity and lower-quality studies

Adverse events reported in <25% across pooled studies, most commonly loss of effectiveness, infection, pain, and lead migration

Fecal Incontinence / LARS: Randomized trials and multiple systematic reviews/meta-analyses show significant reductions in LARS and FI scores and improved quality of life; pooled success rates often in the 76–83% range but with notable revision (~35.2%) and explant (~19.7%) rates

Coverage criteria by indication

Coverage supported when guideline criteria and conservative therapy failure are met; trial phase required to predict success.

Overactive bladder (OAB): SNM may be offered for OAB in patients with inadequate response to or intolerable side effects from pharmacologic or behavioral therapy; typically positioned as a third-line option for severe refractory OAB in carefully selected patients willing to undergo surgeryfailure of conservative and pharmacologic therapy

Guideline panels (AUA/ICS/EAU) endorse SNM with recognition of potential device-related adverse events

Fecal incontinence (FI): SNM should be considered for bothersome FI that has failed conservative measures; may be offered after low anterior resection when conservative measures fail and is acceptable even with an anal sphincter defectfailure of conservative therapy (e.g., >=3 months)

AGA/ICS/EAU guidance supports use and recommends test-phase selection (PNE/Stage)

Constipation / slow transit constipation (STC):

Covered when test-proven benefit and no contraindications

Coverage considerations and common criteria from clinical guidance and technology assessments:

General candidate criteria: Candidate should have failed conservative measures; for bowel dysfunction a 2–3 week bowel diary is recommended prior to testing; test stimulation (PNE or Stage) must demonstrate symptomatic improvement (commonly ≥50%) to proceed to permanent implant≥50% improvement commonly used

PNE duration typically 7 days for bladder and 10–21 days for bowel; Stage test typically 2–3 weeks

Indications supported by guidelines: SNM is supported by guideline bodies for fecal incontinence, refractory overactive bladder after failure of conservative measures, and selected cases of non-obstructive urinary retention; guideline strength and recommended placement in pathway vary by organization

Guideline recommendations (ICS, AUA, NICE, EAU) differ in specifics but consistently value the trial phase

Contraindications preventing coverage: Absolute contraindications include insufficient clinical response to a therapeutic trial, inability to operate the device without suitable caregivers, and pregnancy; relative contraindications include severe or rapidly progressive neurologic disease, complete spinal cord injury, expected need for future MRI below the head, and abnormal sacral anatomy

Sacral nerve stimulation is not appropriate when symptoms are clearly secondary to another cause. Exclusions include urinary or bowel dysfunction that is secondary to neurologic disease (for example, Parkinson’s disease, stroke, spinal cord injury, or multiple sclerosis), or when dysfunction is caused by a bladder outlet or mechanical obstruction (for example benign prostatic hyperplasia, tumor- or radiation-induced obstruction, or urethral stricture). For fecal indications, SNM is excluded when fecal incontinence is secondary to constipation or when distorted anorectal anatomy (for example anorectal malformation, abscess/fistula, or prior rectal surgery) explains symptoms.

Clinical trials that informed policy commonly excluded participants with comorbid conditions that could confound outcomes. Typical trial exclusion criteria included significant neurological disorders, uncontrolled diabetes, active urinary tract infection, stress urinary incontinence, and recent onabotulinumtoxinA (Botox) treatment within the prior nine months.

Certain conditions are absolute contraindications to permanent SNM implantation. Pregnancy is listed as an absolute contraindication. Other absolute exclusions include an insufficient clinical response to a therapeutic test trial and inability of the individual to operate the device when no supportive caregivers are available to assist.

Relative contraindications that may preclude SNM candidacy include severe or rapidly progressive neurologic disease, an established complete spinal cord injury, anticipated need for future MRI of body regions below the head, and abnormal sacral anatomy. These factors should be weighed individually when assessing candidacy.

When applying this policy, the terms of the member’s benefit plan govern. If federal, state, or contractual requirements conflict with this policy, those requirements take precedence; verify applicable coverage terms before relying on the policy guidance.

Sacral nerve stimulation for the treatment of Constipation and Chronic Pelvic Pain is considered unproven and not medically necessary due to insufficient evidence of safety and/or efficacy and is not supported as a routine therapy in this policy.

Evidence for SNM in chronic pelvic pain is limited and heterogeneous. Systematic reviews and available studies do not provide sufficient high-quality, consistent evidence to support SNM as a definitive therapy for chronic pelvic pain; additional well‑designed randomized trials are required.

The evidence base for SNM to treat constipation (including refractory idiopathic slow transit constipation) is inconclusive. Randomized trials and systematic reviews report conflicting results, substantial adverse event and reoperation rates in some series, and uncertainty about long‑term benefit; consequently SNM for constipation is considered insufficiently supported for routine use.

Although some societies recognize potential benefit, the American Society of Colon and Rectal Surgeons notes that SNM is not currently FDA‑approved for constipation in the United States and that additional evidence is required to define appropriate patient selection; this limits routine coverage and supports a cautious or research‑focused approach.

Provider Actions, Documentation & Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization required per policy criteria for sacral nerve stimulation (SNS) screening trials and permanent implantation. Prior authorization may also be required for revisions, replacements, and removals. Verify benefit plan prior authorization processes and submit required medical record documentation (see items).

Affected codes include — CPT/HCPCS examples: 0784T, 0785T, 0786T, 0787T, 64561, 64581, 64585, 64590, and related generator revision/removal codes (see Applicable Codes).
Prior authorization does not guarantee coverage; coverage determined by federal/state/contractual requirements.

Documentation Required

Successful Test Stimulation Requirement

A successful test stimulation (percutaneous nerve evaluation [PNE] or Stage/temporary lead test) is required prior to permanent implantation and is generally defined as achievement of ≥50% improvement in the member’s primary troublesome urinary or bowel symptom(s) (for urinary indications: ≥50% reduction in urgency urinary incontinence or frequency or return to <8 voids/day). Documentation of voiding/bowel diaries and validated outcome scores should support the reported improvement.

Procedure, Device and Diagnosis Codes

Procedure CPT/T codesCPT

0784T	Insertion or replacement of percutaneous electrode array, spinal, with integrated neurostimulator; including imaging guidance, when performed.
0785T	Revision or removal of neurostimulator electrode array, spinal, with integrated neurostimulator.
0786T	Insertion or replacement of percutaneous electrode array , sacral, with integrated neurostimulator, including imaging guidance, when performed.
0787T	Revision or removal of neurostimulator electrode array, sacral, with integrated neurostimulator.
64561	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed.
64581	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement).
64585	Revision or removal of peripheral neurostimulator electrode array.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver; requiring pocket creation and connection between electrode array and pulse generator or receiver.

HCPCS device codesHCPCS

L8679	Implantable neurostimulator; pulse generator; any type.
L8680	Implantable neurostimulator electrode, each.
L8682	Implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.

Selected ICD-10 diagnosis codes (urinary and fecal indications)ICD-10

N32.81	Overactive bladder.
N32.9	Bladder disorder, unspecified.
N39.3	Stress incontinence (female) (male).
N39.41	Urge incontinence.
N39.42	Incontinence without sensory awareness.
N39.46	Mixed incontinence.
N39.490	Overflow incontinence.
R15.9	Full incontinence of feces.

Applicable ICD-10 diagnosis codes (added/removed)ICD-10

R35.81	exact ICD-10 code added to Urinary Indications
R35.89	exact ICD-10 code added to Urinary Indications
R39.191	exact ICD-10 code added to Urinary Indications
R39.192	exact ICD-10 code added to Urinary Indications
R39.198	exact ICD-10 code added to Urinary Indications
R35.8	ICD-10 code removed
R39.19	ICD-10 code removed

Postvoid residual (PVR) threshold for chronic urinary retention

PVR threshold>= 300 mL

Duration requirementPersists for 2–6 months

Documentation frequencyDocumented on >=2 separate occasions

Definitions and Key Terms

Chronic Urinary Retention

DefinitionPostvoid residual (PVR) >= 300 mL

PersistencePersists for 2–6 months

VerificationDocumented on >=2 separate occasions

Fecal Incontinence

DefinitionInvoluntary passage of fecal matter or inability to control discharge of bowel contents

Severity rangeRanges from involuntary passage of flatus to complete evacuation

Context

Background and Evidence Context

Sacral neuromodulation (SNM/SNS) modulates sacral nerve roots via an implanted electrode and pulse generator and is used for selected indications including overactive bladder, nonobstructive urinary retention, and fecal incontinence. The therapy typically begins with a temporary trial stimulation to predict response; permanent implantation is considered when the trial documents a clinically meaningful benefit (commonly defined as ≥50% improvement). Commercial systems include Medtronic InterStim and Axonics devices, and clinical and regulatory guidance inform patient selection, testing durations, and contraindications.

Policy Revision History

2025-10-01state_version_createdLatest

Created state-specific policy version for Nebraska (no change to coverage guidelines).

OpenPayer

Sacral Nerve Stimulation for Urinary and Fecal Indications (for Nebraska Only)

Coverage Criteria for Sacral Nerve Stimulation

Provider Actions, Documentation & Prior Authorization

Procedure, Device and Diagnosis Codes

Definitions and Key Terms

Background and Evidence Context

Policy Revision History